Table 1.
Quality of Life and PRO assessments to evaluate disease burden and control
Assessment | Application | Number of items | Recall period(s) | Advantages | Disadvantages |
---|---|---|---|---|---|
Angioedema Activity Score (AAS) [51] | Recurrent angioedema | 5 | 24 h |
Brief Good internal consistency |
Prospective nature limits compliance |
HAE Activity Score (HAE-AS) [52] | HAE-C1-INH | 12 | 1 month and 6 months | Allows for assessment of attack variability over time | Requires accurate recall over 6 months |
Angioedema Quality of Life (AE-QoL) Questionnaire [57] |
Recurrent angioedema | 17 | 4 weeks |
Good psychometric properties Good internal consistency |
Time-consuming Not HAE specific |
Hereditary angioedema quality of life (HAE-QoL) [61] | HAE-C1-INH | 25 | 6 months |
HAE specific Good internalconsistency |
Time-consuming Requires accurate recall over 6 months |
United States Hereditary Angioedema Association Quality of Life (HAEA-QoL) Survey [65] | HAE-C1-INH | 27 | NR | NR | Validation studies are needed |
36-Item Short-Form Health Survey (SF-36) [54, 93] | Generic health status | 36 | 1 week and 4 weeks | Useful for comparisons |
Less specific Low sensitivity |
EuroQol 5-Dimensions Survey (EQ-5D) [54, 94] | Generic health status | 5 | No recall period |
Useful for comparisons Easy to administer |
Less specific Low sensitivity |
Angioedema Control Test (AECT) [59] | Recurrent angioedema | 4 | 4 weeks and 3 months |
Brief Simple scoring |
Validation studies are needed |
HAE, hereditary angioedema; HAE-C1-INH, HAE with C1-esterase inhibitor deficiency; NR, not reported; PRO, patient-reported outcome